New Frontiers in Osteoporosis Therapy
- PMID: 31509477
- DOI: 10.1146/annurev-med-052218-020620
New Frontiers in Osteoporosis Therapy
Abstract
Current osteoporosis medications reduce fractures significantly but have rare and serious adverse effects (osteonecrosis of the jaw, atypical femoral fractures) that may limit their safety for long-term use. Insights from basic bone biology and genetic disorders have led to recent advances in therapeutics for osteoporosis. New approaches now in clinical use include the antisclerostin monoclonal antibody romosozumab, as well as the parathyroid hormone-related peptide analog abaloparatide. Clinical trial data show significant antifracture benefits with recently approved romosozumab. Studies using abaloparatide build on our longstanding experience with teriparatide and the importance of consolidating the bone mineral density gains achieved from an anabolic agent by following it with an antiresorptive. Combination and sequential treatments using osteoporosis medications with different mechanisms of action have also been tested with promising results. On the horizon is the potential for cell-based therapies (e.g., mesenchymal stem cells) and drugs that target the elimination of senescent cells in the bone microenvironment.
Keywords: abaloparatide; bisphosphonate; denosumab; fracture; osteoporosis; romosozumab; teriparatide.
Similar articles
-
Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.Maturitas. 2019 Nov;129:12-22. doi: 10.1016/j.maturitas.2019.08.003. Epub 2019 Aug 10. Maturitas. 2019. PMID: 31547908
-
New therapeutic targets for osteoporosis.Maturitas. 2019 Feb;120:1-6. doi: 10.1016/j.maturitas.2018.11.010. Epub 2018 Nov 16. Maturitas. 2019. PMID: 30583758 Review.
-
Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy.Curr Osteoporos Rep. 2017 Apr;15(2):110-119. doi: 10.1007/s11914-017-0353-4. Curr Osteoporos Rep. 2017. PMID: 28303448 Free PMC article. Review.
-
Osteoanabolic and dual action drugs.Br J Clin Pharmacol. 2019 Jun;85(6):1084-1094. doi: 10.1111/bcp.13766. Epub 2019 Apr 3. Br J Clin Pharmacol. 2019. PMID: 30218587 Free PMC article. Review.
-
A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture.Clin Ther. 2017 Jul;39(7):1276-1290. doi: 10.1016/j.clinthera.2017.05.348. Epub 2017 Jun 17. Clin Ther. 2017. PMID: 28629610
Cited by
-
The biomedical applications of nanozymes in orthopaedics based on regulating reactive oxygen species.J Nanobiotechnology. 2024 Sep 16;22(1):569. doi: 10.1186/s12951-024-02844-3. J Nanobiotechnology. 2024. PMID: 39285458 Free PMC article. Review.
-
The Discovery of a Specific CKIP-1 Ligand for the Potential Treatment of Disuse Osteoporosis.Int J Mol Sci. 2024 Aug 15;25(16):8870. doi: 10.3390/ijms25168870. Int J Mol Sci. 2024. PMID: 39201556 Free PMC article.
-
Towards an enhanced understanding of osteoanabolic effects of PTH-induced microRNAs on osteoblasts using a bioinformatic approach.Front Endocrinol (Lausanne). 2024 Jul 17;15:1380013. doi: 10.3389/fendo.2024.1380013. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39086902 Free PMC article.
-
Persistent Mesodermal Differentiation Capability of Bone Marrow MSCs Isolated from Aging Patients with Low-Energy Traumatic Hip Fracture and Osteoporosis: A Clinical Evidence.Int J Mol Sci. 2024 May 12;25(10):5273. doi: 10.3390/ijms25105273. Int J Mol Sci. 2024. PMID: 38791313 Free PMC article.
-
Natural Compounds for Bone Remodeling: A Computational and Experimental Approach Targeting Bone Metabolism-Related Proteins.Int J Mol Sci. 2024 May 6;25(9):5047. doi: 10.3390/ijms25095047. Int J Mol Sci. 2024. PMID: 38732267 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
